- Home
- JZXN vs INDP Comparison
JZXN vs INDP Comparison
Compare JZXN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- INDP
- Stock Information
- Founded
- JZXN 2017
- INDP 2000
- Country
- JZXN China
- INDP United States
- Employees
- JZXN N/A
- INDP N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- INDP Health Care
- Exchange
- JZXN Nasdaq
- INDP Nasdaq
- Market Cap
- JZXN 10.7M
- INDP 10.2M
- IPO Year
- JZXN 2021
- INDP N/A
- Fundamental
- Price
- JZXN $1.59
- INDP $0.94
- Analyst Decision
- JZXN
- INDP Strong Buy
- Analyst Count
- JZXN 0
- INDP 2
- Target Price
- JZXN N/A
- INDP $8.50
- AVG Volume (30 Days)
- JZXN 773.4K
- INDP 25.8K
- Earning Date
- JZXN 01-03-2025
- INDP 11-12-2024
- Dividend Yield
- JZXN N/A
- INDP N/A
- EPS Growth
- JZXN N/A
- INDP N/A
- EPS
- JZXN N/A
- INDP N/A
- Revenue
- JZXN $7,597,423.00
- INDP N/A
- Revenue This Year
- JZXN N/A
- INDP N/A
- Revenue Next Year
- JZXN N/A
- INDP N/A
- P/E Ratio
- JZXN N/A
- INDP N/A
- Revenue Growth
- JZXN 81.94
- INDP N/A
- 52 Week Low
- JZXN $1.00
- INDP $0.84
- 52 Week High
- JZXN $67.60
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- JZXN 53.88
- INDP 40.51
- Support Level
- JZXN $1.31
- INDP $0.94
- Resistance Level
- JZXN $1.65
- INDP $1.01
- Average True Range (ATR)
- JZXN 0.38
- INDP 0.06
- MACD
- JZXN 0.01
- INDP 0.00
- Stochastic Oscillator
- JZXN 46.34
- INDP 28.24
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.